Krystal Biotech Inc. Company Profile
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 327.35 +0.02%
Krystal Biotech at a glance
Krystal Biotech Inc. (NASDAQ: KRYS) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Pittsburgh, PA. Krystal Biotech is led by Mr. Krish S. Krishnan M.B.A., M.S. and employs about 295 people. The company's shares have traded publicly since 2017.
At a market capitalization of $9.61 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001711279, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Krystal Biotech do?
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Krystal Biotech Inc.
- Ticker
- NASDAQ: KRYS
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Krish S. Krishnan M.B.A., M.S.
- Employees
- 295
- Headquarters
- 2100 Wharton Street, Pittsburgh, PA, United States
- Phone
- 412 586 5830
- Website
- krystalbio.com
- IPO year
- 2017
- Market cap
- $9.61B
- SEC CIK
- 0001711279
- Latest annual report
- 10-K · Feb 17, 2026
Companies similar to Krystal Biotech
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PCVXVaxcyte Inc. | 65.02 | -2.90% | $9.67B | vs KRYS |
| QGENQiagen N.V. | 44.53 | -0.58% | $9.20B | vs KRYS |
| TWSTTwist Bioscience Corporation | 152.05 | -2.31% | $10.08B | vs KRYS |
| KYMRKymera Therapeutics Inc. | 109.30 | +0.88% | $8.99B | vs KRYS |
| RGENRepligen Corporation | 163.84 | -2.02% | $10.40B | vs KRYS |
| IBRXImmunityBio Inc. | 9.91 | +1.64% | $10.50B | vs KRYS |
| TECHBio-Techne Corp | 72.45 | -0.11% | $11.36B | vs KRYS |
| HALOHalozyme Therapeutics Inc. | 109.84 | -0.86% | $12.47B | vs KRYS |